Gedeon Richter Strikes $16.5m Global Tocilizumab Deal
Agreement For Biosimilar To Actemra/RoActemra Reached With Taiwan’s Mycenax
Gedeon Richter has struck a deal worth $16.5m with Taiwan’s Mycenax for global rights to a tocilizumab biosimilar version of Actemra/RoActemra, setting a date for planned launches in the EU, Japan, Canada and Australia.
You may also be interested in...
Fresenius Kabi has followed a US filing for its MSB11456 proposed tocilizumab biosimilar with a parallel marketing authorization application in the EU for its rival to RoActemra.
Fresenius Kabi has been tipped to strike first in the race to launch a biosimilar to Actemra – a market where competition “is likely to be thin for some time.”
Celltrion has provided the latest update on progress for its CT-P47 proposed tocilizumab biosimilar, with Phase III trials set to begin for its rival to Actemra/RoActemra.